Genomic & Biopharma News

Does Pfizer's Xeljanz share its CV safety questions with burgeoning JAK class?
Pfizer’s rheumatoid arthritis drug Xeljanz has run into safety issues with its higher dose. But whether the issues belong to Xeljanz alone—rather than to its burgeoning class of JAK inhibitors—remains to be seen.
Fierce Pharma, 2019-02-22 13:56:56

AbbVie’s cancer drug Venclexta blocks diabetes in mice by targeting beta cell ‘senescence’ 
A UCSF team found that beta cells experience "secretory senescence," a process whereby DNA damage causes them to stop working properly. That touches off the immune attack on beta cells that's characteristic of Type 1 diabetes. In mice, a drug that eradicates senescent cells—AbbVie’s leukemia treatment Venclexta—prevented the onset of the disease.
Fierce Biotech, 2019-02-22 13:43:57

Palm Beach Post: ORB Leaves Palm Beach County for New Lab Space
David Willoughby lives in Palm Beach Gardens and, until recently, worked there too. But the owner of Ocean Ridge Biosciences wanted to expand, and he couldn't find suitable space in northern Palm Beach County. Please read the PDF for more details
ORB Company News, 2016-12-02 15:35:33

Doubling down on R&D, Daiichi makes executive changes across its U.S. research unit
Japanese pharma Daiichi Sankyo is looking to boost its research focus with a series of changes across its R&D.
Fierce Biotech, 2019-02-22 13:43:27

Palm Beach Post: ORB Leaves Palm Beach County for New Lab Space
David Willoughby lives in Palm Beach Gardens and, until recently, worked there too. But the owner of Ocean Ridge Biosciences wanted to expand, and he couldn't find suitable space in northern Palm Beach County. Please read the PDF for more details
ORB Company News, 2016-12-02 15:35:33

Achieve climbs on data from smoking cessation clinical trial
Achieve Life Sciences has shared final data from a phase 1/2 trial of its smoking cessation candidate cytisinicline. The data show the smoking reductions disclosed one year ago occurred within two days of treatment, sending the nanocap’s stock up as much as 90% in premarket trading.
Fierce Biotech, 2019-02-22 13:35:03

FiercePharmaAsia—GSK-Bharat vaccine deal; Dr. Reddy’s roller coaster; Sandoz sells U.S. generics
GlaxoSmithKline sells an Indian rabies vaccine subsidiary to Bharat Biotech; Dr. Reddy's stock hits a 17-year low on news of an FDA Form 483 but regains ground on another plant's clearance; Novartis' Sandoz sells eight U.S. generics to India's Beximco and more.
Fierce Pharma, 2019-02-22 12:40:20

I-O startup Geneos raises $10.5M for neoantigen drugs
Inovio Pharma spinout Geneos Therapeutics has closed a $10.5 million first-round financing that will help launch its R&D in neoantigen-targeting cancer immunotherapies.
Fierce Biotech, 2019-02-22 12:39:06

Catalyst plays the R&D card to defend Firdapse’s $375K sticker against Bernie Sanders' ire
Caught in the crosshairs of Sen. Bernie Sanders, I-Vt., Catalyst Pharma has come up with a rationale for the $375,000 price tag on its rare disease therapy Firdapse—and it includes some well-worn arguments often invoked by biopharma companies.
Fierce Pharma, 2019-02-22 10:27:58

Opiant dumps bulimia nervosa program after phase 2 flop
A phase 2 trial of Opiant Pharmaceuticals’ naloxone nasal spray OPNT001 in bulimia nervosa has missed its primary and key secondary endpoints. The wipeout prompted Opiant to stop development of OPNT001 in the indication and double down on the rest of its pipeline.
Fierce Biotech, 2019-02-22 10:07:35

Invasive surgeries could be avoided with new pacemakers powered by heartbeats
Researchers have developed a small, flexible, elastic skeleton bound to two piezoelectric composites, which uses the electrical activity of the heart for power.
News Medical Life Sciences, 2019-02-22 09:25:17